Every Form 4 that Thermo Fisher Scientific Inc. (TMO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMO filings page.
Thermo Fisher Scientific senior vice president and CFO Stephen Williamson reported an acquisition of 1,534 shares of common stock linked to a performance-based restricted stock unit award granted on February 19, 2025. On February 25, 2026, the Compensation Committee certified that the required performance goals were met.
Following this award, Williamson directly owns 33,421.193 shares of common stock. The filing also notes an indirect holding of 12,674 shares held "By SLAT," for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Thermo Fisher Scientific Executive Vice President & COO Michel Lagarde acquired 2,231 shares of common stock through a performance-based restricted stock unit award. The award was originally granted on February 19, 2025, and the Compensation Committee certified achievement of the performance criteria on February 25, 2026.
The award vests in three equal tranches on February 28, 2026, 2027 and 2028, subject to the terms of the award agreement. Following this grant, Lagarde directly owns 86,347.909 shares of Thermo Fisher Scientific common stock.
Thermo Fisher Scientific senior vice president and chief HR officer Lisa P. Britt reported equity awards that increase her direct ownership in the company. She received a grant of stock options for 5,139 shares at an exercise price of $0.00 per option, along with grants of 872 and 1,173 shares of common stock.
The common stock relates to a performance-based restricted stock unit award originally granted on February 19, 2025, for which the compensation committee determined on February 25, 2026, that the performance criteria were satisfied. One-third of these shares vest on February 28, 2026 and 2027, with the remaining third vesting on February 28, 2028 subject to adjustment based on total shareholder return CAGR versus a peer group over the period from January 1, 2025 through December 31, 2027. The option award vests in four equal annual installments beginning on February 28, 2027.
Thermo Fisher Scientific Executive Vice President Frederick M. Lowery reported an equity award and updated share holdings. He acquired 1,638 shares of common stock through a performance-based restricted stock unit award originally granted on February 19, 2025, after the Compensation Committee certified performance on February 25, 2026. The award is scheduled to vest in three equal tranches on February 28, 2026, 2027, and 2028. A separate performance-based award granted on February 22, 2023 was reduced by 15% based on relative total shareholder return, resulting in 64 fewer shares than previously reported. Between December 2, 2025 and February 26, 2026, he also acquired 10.854 shares of TMO common stock in the company’s 401(k) plan and reports additional indirect holdings through a limited liability company, while disclaiming beneficial ownership of indirectly held shares except for any pecuniary interest.
Thermo Fisher Scientific senior vice president and general counsel Thomas B. Shropshire Jr. reported equity awards on common stock and stock options. He received a grant of stock options for 4,281 shares at an exercise price of $0.0000 and a separate award of 978 shares of common stock, both recorded as direct ownership.
The filing notes that the option grant vests in four equal annual installments beginning on February 28, 2027, meaning the right to exercise the full option stretches over four years from that date.
Shafer Michael D reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported equity awards and adjustments to his holdings. He received a grant of 13,698 stock options and two performance-based stock unit-related common stock awards totaling 4,698 shares.
The filing explains that a performance-based restricted stock unit award granted on February 19, 2025 met its performance criteria on February 25, 2026, with one-third of the shares vesting on February 28, 2026 and 2027, and the final third vesting on February 28, 2028 subject to potential positive or negative adjustment. It also records a 15% reduction to the final tranche of an earlier 2023 performance-based award, resulting in 56 fewer shares than previously reported. The new stock option vests in four equal annual installments beginning on February 28, 2027.
Thermo Fisher Scientific VP & Chief Accounting Officer Joseph R. Holmes reported equity awards tied to performance-based stock programs. He acquired 985 stock options at an exercise price of $0.0000 per option and 433 shares of common stock as a performance-based restricted stock unit award.
An additional 337 shares of common stock were reported as an adjustment to the final tranche of a 2023 performance-based restricted stock unit award after a 15% reduction in the payout, which resulted in 6 fewer shares than previously reported. The new option grant vests in four equal annual installments beginning on February 28, 2027, and the 2025 performance-based award vests in thirds on February 28, 2026, 2027, and 2028, with the last third still subject to long-term total shareholder return performance.
Pettiti Gianluca reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific executive vice president Gianluca Pettiti reported equity awards that increase his direct holdings in company stock. He received a grant of stock options for 16,270 shares and performance-based restricted stock units that resulted in 2,057 and 3,715 shares of common stock being credited to him.
The performance-based award was granted on February 19, 2025, and the company’s compensation committee determined on February 25, 2026 that its performance criteria were satisfied. One-third of these shares vest on February 28, 2026 and 2027, while the remaining one-third vests on February 28, 2028 and may be adjusted up or down based on relative total shareholder return performance. The stock option grant vests in four equal annual installments beginning on February 28, 2027.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper reported equity awards tied to performance and long-term incentives. He acquired 32,109 stock options at an exercise price of $0.00 per share, which vest in four equal annual installments beginning on February 28, 2027.
He also acquired 7,515 and 7,333 shares of common stock through performance-based restricted stock unit awards granted in February 2025, after the compensation committee determined on February 25, 2026 that performance criteria were satisfied. One-third of these shares vest on February 28, 2026 and February 28, 2027, with the remaining one-third vesting on February 28, 2028 subject to adjustment based on relative total shareholder return CAGR.
The filing also lists indirect holdings in Thermo Fisher shares by the Alison Casper 2020 Irrevocable Trust, Floral Park Associates, Inc., and the MNC 2020 Irrevocable Trust, for which Casper disclaims beneficial ownership except for any pecuniary interest.
Thermo Fisher Scientific executive vice president Gianluca Pettiti sold 400 shares of common stock in an open-market transaction at $541.20 per share. The sale on February 9, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.
After this transaction, Pettiti directly beneficially owned 20,752.223 shares of Thermo Fisher Scientific common stock. Rule 10b5-1 plans allow insiders to schedule trades in advance, helping separate personal trading decisions from later corporate developments.
Thermo Fisher Scientific director reports additional deferred stock units. A Thermo Fisher Scientific Inc. (TMO) director filed a Form 4 for a transaction dated 12/31/2025. The filing shows an acquisition of 53.93 phantom stock units, each convertible into one share of common stock, recorded in Table II as a derivative security held directly.
The 53.93 units were credited at a price of $579.45 per unit under the company’s Deferred Compensation Plan for Directors. Under this plan, quarterly director retainers are deferred into common stock units based on the closing stock price at quarter end. The underlying shares are scheduled to be distributed in stock when the director’s service ends for any reason or upon a change of control.
Thermo Fisher Scientific director reports deferred stock units grant
A Thermo Fisher Scientific Inc. director, R. Alexandra Keith, reported an acquisition of 53.93 phantom stock units on December 31, 2025 under the company’s Deferred Compensation Plan for Directors. These units are credited based on the closing stock price at quarter end, which was $579.45 per unit, and each unit is convertible into one share of common stock. Following this transaction, the director beneficially owns 1,204.42 phantom stock units, which will be distributed in stock after the director’s service ends or if there is a change of control.
Thermo Fisher Scientific director reports deferred stock units under incentive plan. A reporting person serving as a director of Thermo Fisher Scientific Inc. (TMO) disclosed a routine change in holdings through a Form 4 filing. On December 31, 2025, the director received 73.35 phantom stock units, each convertible into one share of common stock, under the company’s Deferred Compensation Plan for Directors.
The units were credited at a price of $579.45 per unit, based on the closing stock price at quarter end, bringing the director’s total derivative holdings to 17,502.02 stock units held directly. These stock units are designed to mirror common stock and are distributable in shares when the director’s service ends or upon a change of control, aligning director compensation with long‑term shareholder value.
Thermo Fisher Scientific director reports deferred stock unit grant
A Thermo Fisher Scientific Inc. (TMO) director reported receiving 64.72 phantom stock units on December 31, 2025 under the company’s Deferred Compensation Plan for Directors. These units are convertible into common stock on a 1-for-1 basis and were credited at a price of $579.45 per unit, based on the closing stock price at quarter end. Following this transaction, the director beneficially owns 2,638.67 derivative securities, held directly. Under the plan, directors’ retainers are deferred quarterly into common stock units, which are distributable as stock when director service ends for any reason or upon a change of control.
Thermo Fisher Scientific Inc. director transaction: Director Jennifer M. Johnson reported acquiring 53.93 phantom stock units tied to Thermo Fisher common stock on December 31, 2025. The units were credited at a price of $579.45 per unit under the company’s Deferred Compensation Plan for Directors.
Each phantom stock unit is convertible into one share of common stock and is distributable as stock after the director’s service ends or upon a change of control. Following this transaction, Johnson directly holds 595.29 phantom stock units. She is also President and Chief Executive Officer of Franklin Resources, Inc. and disclaims beneficial ownership of Thermo Fisher shares held in Franklin Templeton-managed client accounts.
Thermo Fisher Scientific director reports stock gift
Scott M. Sperling, a director of Thermo Fisher Scientific Inc., reported a transaction in the company’s common stock on December 10, 2025. The filing shows he disposed of 4,386 shares of common stock in a transaction coded "G," indicating a gift, at a reported price of $0 per share. Following this transaction, he beneficially owns 68,980 shares of Thermo Fisher Scientific common stock in direct ownership.
Thermo Fisher Scientific executive Michel Lagarde reported option exercises and a stock sale. On December 4, 2025, he exercised stock options for 18,637 shares of common stock at an exercise price of $105.17 per share and another 22,046 shares at an exercise price of $132.66 per share. On the same day, he sold 22,046 shares of Thermo Fisher Scientific common stock at a weighted average price of $563.56 per share, with individual sale prices ranging from $563.38 to $564.20.
After these transactions, Lagarde beneficially owned 84,116.909 shares of Thermo Fisher Scientific common stock in direct form. The options exercised had previously vested in scheduled installments in 2017, 2018, 2019 and 2020, and following the reported exercises, the specific option grants referenced now show 0 derivative securities remaining.
Thermo Fisher Scientific Inc. executive Michel Lagarde reported multiple stock option exercises and related stock sales. As Executive Vice President & COO, he filed a Form 4 for transactions dated December 2 and 3, 2025.
On December 2, Lagarde exercised options to acquire 36,000 shares of common stock at an exercise price of $105.17 per share, then sold 30,000 shares at a weighted average price of $581.92. On December 3, he exercised options for another 68,000 shares at $105.17, and sold 29,479 shares at a weighted average price of $583.33 plus 2,521 shares at a weighted average price of $584.11.
After these transactions, Lagarde directly held 65,479.909 shares of Thermo Fisher common stock and 18,637 stock options with a $105.17 exercise price expiring on July 20, 2026, which had vested in two equal installments on August 29, 2017 and 2020.
Thermo Fisher Scientific executive Thomas B. Shropshire, Jr., who serves as SVP and General Counsel, reported a change in his holdings of the company’s common stock. On 12/02/2025, he disposed of 337.476 shares of Thermo Fisher common stock in a transaction coded “F” at a price of $580.37 per share. After this transaction, he beneficially owned 5,079.524 shares, held directly.
Thermo Fisher Scientific executive Frederick M. Lowery, an Executive Vice President, reported option exercises and related stock sales in early December 2025. On December 1, 2025, he exercised 6,913 stock options at $253.99 per share and sold 6,913 shares of common stock at $597.68 per share. On December 2, 2025, he exercised an additional 6,912 options at $253.99 and sold 6,912 shares at $581.94 per share. After these transactions, he directly owned 14,367.3724 shares of Thermo Fisher common stock, with additional indirect holdings of 1,175.83 shares through a 401(k) plan and 5.036 shares through a limited liability company. The transactions were carried out under a Rule 10b5-1 trading plan adopted on August 28, 2025.
Thermo Fisher Scientific Inc. (TMO) executive vice president Michael D. Shafer reported option exercises and related stock sales. On November 25, 2025, he exercised stock options for 8,475 shares at $253.99 and 2,250 shares at $294.02, then sold the same amounts of common stock at $600 per share.
These transactions were carried out under a Rule 10b5-1 trading plan adopted on November 20, 2024. After the reported trades, Shafer directly beneficially owned 18,730.8026 shares of Thermo Fisher common stock, and the exercised options reported in this filing no longer remain outstanding.
Thermo Fisher Scientific Inc. (TMO) senior vice president and chief financial officer Stephen Williamson reported an insider transaction involving company common stock. On 11/14/2025, he transferred 433 shares of Thermo Fisher common stock in a transaction coded "G," which indicates a gift, at a reported price of $0 per share. Following this transaction, he beneficially owned 31,887.193 shares of common stock directly. He also had 12,674 shares reported as indirectly owned through a SLAT, and he disclaims beneficial ownership of those indirect shares except to the extent of any pecuniary interest.
Thermo Fisher Scientific (TMO) reported an insider transaction by its Sr. VP and Chief HR Officer. On 11/12/2025, the officer sold 1,057.577 shares of common stock at a price of $588.265 per share (Transaction Code S).
Following the sale, the officer’s beneficial ownership is 13,087.227 shares, held directly. No derivative securities were reported in this filing.
Thermo Fisher Scientific (TMO) reported an insider transaction by EVP & COO Michel Lagarde. On 11/13/2025, he exercised 4,638 stock options at $253.99 per share (code M), acquiring common stock, and then sold 4,638 shares at a $594.42 weighted average price (code S). Following these transactions, his directly held common stock was 23,479.909 shares. The sale price reflected multiple trades between $594.36 and $594.88. The option, with a $253.99 exercise price, was originally scheduled to vest in four equal installments on February 26 of 2020–2023 and carried an expiration of 02/26/2026.
Thermo Fisher Scientific (TMO) reported insider transactions by an Executive Vice President on 11/10/2025 under a Rule 10b5-1 trading plan. The officer exercised 725 options at $253.99 and 2,250 options at $294.02, then sold 725 shares and 2,250 shares at $580.
Following these transactions, the officer beneficially owned 21,152.223 shares of common stock, held directly. The options exercised were previously granted and had vested in four equal annual installments ending in 2023.
Thermo Fisher Scientific (TMO) reported insider transactions by an officer (Sr. VP and Chief HR Officer) on 11/07/2025. The filer sold 1,750 shares of common stock at $571.3977, exercised 8,475 stock options at $253.99, and sold 8,475 shares at $571.6701. Following these trades, the filer directly owned 14,144.804 shares.
The exercised option related to a grant that vested in four equal installments on February 26, 2020, 2021, 2022, and 2023.
Thermo Fisher Scientific (TMO) disclosed a routine insider transaction on Form 4. Executive Vice President Gianluca Pettiti sold 400 shares of common stock on 10/24/2025 at $574.15 per share (transaction code S). After the sale, he beneficially owned 21,152.223 shares, held directly. The transaction was effected under a Rule 10b5-1 trading plan adopted on February 10, 2025.
Thermo Fisher Scientific (TMO) reported insider activity by Chairman & CEO Marc N. Casper. On 10/24/2025 and 10/27/2025, he exercised stock options for 17,104 and 7,250 shares, respectively, at an exercise price of $253.99 per share, and sold the same number of shares on each date in multiple transactions at weighted average prices as disclosed.
Following these transactions, his direct beneficial ownership was 113,762.285 shares. He also reported indirect holdings of 11,300 shares by the Alison Casper 2020 Irrevocable Trust, 14,608 shares by Floral Park Associates, Inc., and 5,000 shares by the MNC 2020 Irrevocable Trust. The trades were conducted under a Rule 10b5-1 trading plan adopted on April 28, 2025.
Dion J. Weisler, a director of Thermo Fisher Scientific, reported a Section 16 transaction dated 09/27/2025. The filing shows Phantom Stock Units were acquired under the company's Deferred Compensation Plan for Directors and are convertible 1-for-1 into common stock. The report states units were credited at $464.24 per unit and lists 80.78 as the number associated with the reported acquisition and 2,573.95 as the amount of common stock beneficially owned following the transaction. The units are distributable as stock upon cessation of director service or a change of control. The form was signed by an attorney-in-fact on 09/30/2025.
Scott M. Sperling, a director associated with Thomas H. Lee Partners, received 17,428.67 phantom stock units in Thermo Fisher Scientific (TMO) on 09/27/2025 under the company's Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock on a 1-for-1 basis and was credited at a per-unit value of $464.24, reflecting the quarter-end closing price used to calculate director retainer deferrals. The units are distributable as shares when director service ends or if a change of control occurs. The filing documents a grant of stock-linked deferred compensation rather than an open-market purchase or sale.
Keith R. Alexandra, a director of Thermo Fisher Scientific (TMO), reported a grant of 67.31 Phantom Stock Units credited on 09/27/2025 under the company's Deferred Compensation Plan for Directors. The units convert into common stock on a 1-for-1 basis and were credited at a recorded price of $464.24 per unit. The filing shows 1,150.49 shares beneficially owned following the reported transaction. The Plan states deferred director retainers are recorded as common stock units based on quarter-end closing prices and are distributable as stock upon cessation of director service or a change of control. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
Karen S. Lynch, a director of Thermo Fisher Scientific (TMO), was credited with 67.31 phantom stock units on 09/27/2025 under the company's Deferred Compensation Plan for Directors. Each unit is convertible 1-for-1 into common stock and was recorded at a deferred unit price of $464.24 per unit. The units are payable as shares upon the director's cessation of service or upon a change of control. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Lynch on 09/30/2025. Following the reported transaction, the filing indicates 171.54 derivative units beneficially owned in a direct form.
Jennifer M. Johnson, a director of Thermo Fisher Scientific Inc. (TMO), was credited with 67.31 Phantom Stock Units on September 27, 2025 under the issuer's Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock on a 1-for-1 basis and the units were credited at a stated price of $464.24 per unit. The units are distributable as stock when the director ceases service or upon a change of control. The filing notes the reporting person is an executive at Franklin Resources, Inc., and that Franklin Templeton subsidiaries may hold Thermo Fisher shares in client accounts; the reporting person disclaims beneficial ownership of those third-party holdings.